Professor of Medicine. Director of the Vascular Medicine and Metabolism Unit. University
Hospital “Sant Joan”. IISPV. CIBERDEM. Universitat Rovira i Virgili. Reus. Spain.

Born in Barcelona. He obtained his MD degree in 1976 at Barcelona Autonomous University. .
PhD (1980) at Barcelona Autonomous University. Thesis title: HDL and disease. Specialist in
Internal Medicine (Valle Hebron Hospital-Barcelona) (1981). Post doc in Lipid Metabolism
Disturbances (1983-1984). Saint Thomas Hospital Medical School-London. Chemical Pathology
Department (Prof Barry Lewis): “Lipoprotein kinetics and LDL receptors”. Director of the “Lipid
and Arteriosclerosis Research Unit” and Head of “Vascular Medicine and Metabolism Unit”:
Saint Joan University Hospital. Reus: (Since 1985). Full Professor of Medicine. Rovira I Virgili
University: (1991). Director of Research: Saint Joan University Hospital. Reus: (Since 2009).
President of the Spanish Arteriosclerosis Society (2000-2004). Member of the Executive
Committee of European Atherosclerosis Society (2009-2011). Author of more than 300
research publications (PubMed: Masana L). Director of more than 30 PhD projects.
Fields of interest: Lipoproteins and vascular diseases, diabetes, obesity. Genetic
hyperlipidemias. Fatty acid transporters. New metabolic and cardiovascular risk markers.

Contributions

Panel Discussion: Optimizing Management of HoFH in a Changing Landscape91th EAS Congress 2023Optimizing Management of HoFH in a Changing LandscapeNew evidence in Pediatric HoFH managementOptimizing Management of HoFH in a Changing Landscape91th EAS Congress 2023Lomitapide for the treatment of paediatric homozygous familial hypercholesterolaemia patients - Results from the efficacy phase of the APH-19 study91th EAS Congress 2023Late Breaker - ClinicalRebuttals: Is there a role for diet and nutrition in LDL lowering?91th EAS Congress 2023Is there a role for diet and nutrition in LDL lowering?Panel Discussion: Re-thinking Lipid Management in Patients with High and Very High Cardiovascular RiskRe-thinking Lipid Management in Patients with High and Very High Cardiovascular Risk91th EAS Congress 2023Combination lipid-modifying therapy in high- and very-high-risk patients91th EAS Congress 2023Re-thinking Lipid Management in Patients with High and Very High Cardiovascular RiskImplementation of the 2019 lipid guidelines-where are we now? - Discussion and Q&A90th EAS Congress 2022Implementation of the 2019 lipid guidelines-where are we now?Start with combination therapy and get on with it90th EAS Congress 2022Implementation of the 2019 lipid guidelines-where are we now?EAS Advanced Course in Rare Lipid Disorders - Spanish Lipid AssociationWebinars on-demand(DyslipidemiaReviewLipidologyPrimary Hyperlipidemia)Intensive Lipid lowering- moving beyond statins alone89th EAS Congress 2021(ReviewTreatmentHypolipidemic drugs)Why and in whom is combination needed?88th EAS Congress 2020(ReviewGuidelinesTreatmentHypolipidemic drugs)Optimising cholesterol lowering treatment - How many times do we learn the same lesson?87th EAS Congress 2019Incremental value of established therapies for dyslipidaemic patients86th EAS Congress 2018